Verve Therapeutics/VERV

$7.14

-6.05%
-
1D1W1MYTD1YMAX

About Verve Therapeutics

Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH). VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies.

Ticker

VERV

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sekar Kathiresan

Employees

255

Headquarters

Boston, United States

VERV Metrics

BasicAdvanced
$635.51M
Market cap
-
P/E ratio
-$3.13
EPS
-
Beta
-
Dividend rate
$635.51M
$21.42
$7.36
1.26M
17.239
-27.94%
-34.78%
-29.43%
54.049
1.039
1.06
505.77%
-7.19%

What the Analysts think about VERV

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 8 analysts.
350% upside
High $55.00
Low $15.00
$7.14
Current price
$32.13
Average price target

VERV Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-947.05% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$5.1M
64.52%
Net income
$-48.3M
5.69%
Profit margin
-947.05%
-35.76%

VERV Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 16.06%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.84
-$0.87
-$0.72
-$0.69
-
Expected
-$0.78
-$0.92
-$0.92
-$0.82
-$0.71
Surprise
7.83%
-5.23%
-21.57%
-16.06%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Verve Therapeutics stock?

Verve Therapeutics (VERV) has a market cap of $635.51M as of April 15, 2024.

What is the P/E ratio for Verve Therapeutics stock?

The price to earnings (P/E) ratio for Verve Therapeutics (VERV) stock is 0 as of April 15, 2024.

Does Verve Therapeutics stock pay dividends?

No, Verve Therapeutics (VERV) stock does not pay dividends to its shareholders as of April 15, 2024.

When is the next Verve Therapeutics dividend payment date?

Verve Therapeutics (VERV) stock does not pay dividends to its shareholders.

What is the beta indicator for Verve Therapeutics?

Verve Therapeutics (VERV) does not currently have a Beta indicator.

What is the Verve Therapeutics stock price target?

The target price for Verve Therapeutics (VERV) stock is $32.13, which is 350% above the current price of $7.14. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Verve Therapeutics stock

Buy or sell Verve Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing